- Home
- NEWT vs CAPR Comparison
NEWT vs CAPR Comparison
Compare NEWT & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEWT
- CAPR
- Stock Information
- Founded
- NEWT 1998
- CAPR 2005
- Country
- NEWT United States
- CAPR United States
- Employees
- NEWT N/A
- CAPR N/A
- Industry
- NEWT Major Banks
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NEWT Finance
- CAPR Health Care
- Exchange
- NEWT Nasdaq
- CAPR Nasdaq
- Market Cap
- NEWT 294.8M
- CAPR 324.6M
- IPO Year
- NEWT N/A
- CAPR N/A
- Fundamental
- Price
- NEWT $12.37
- CAPR $6.28
- Analyst Decision
- NEWT Hold
- CAPR Strong Buy
- Analyst Count
- NEWT 4
- CAPR 8
- Target Price
- NEWT $13.00
- CAPR $24.75
- AVG Volume (30 Days)
- NEWT 185.0K
- CAPR 1.4M
- Earning Date
- NEWT 07-28-2025
- CAPR 08-11-2025
- Dividend Yield
- NEWT 6.19%
- CAPR N/A
- EPS Growth
- NEWT 21.23
- CAPR N/A
- EPS
- NEWT 2.01
- CAPR N/A
- Revenue
- NEWT $364,004,000.00
- CAPR $13,392,150.00
- Revenue This Year
- NEWT N/A
- CAPR N/A
- Revenue Next Year
- NEWT $12.73
- CAPR $6,061.53
- P/E Ratio
- NEWT $6.10
- CAPR N/A
- Revenue Growth
- NEWT 20.91
- CAPR N/A
- 52 Week Low
- NEWT $9.12
- CAPR $3.98
- 52 Week High
- NEWT $15.49
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- NEWT 61.20
- CAPR 36.33
- Support Level
- NEWT $12.16
- CAPR $6.17
- Resistance Level
- NEWT $12.48
- CAPR $7.30
- Average True Range (ATR)
- NEWT 0.27
- CAPR 0.43
- MACD
- NEWT 0.02
- CAPR -0.11
- Stochastic Oscillator
- NEWT 73.00
- CAPR 4.53
About NEWT NewtekOne Inc.
NewtekOne Inc is a financial holding company engaged in providing financial solutions to its Client Base. It is an internally managed non-diversified closed-end management investment company. It has four reportable segments Banking, Alternative Lending, Technology, NSBF, and Payments.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.